Your browser doesn't support javascript.
loading
Progesterone abolishes estrogen and/or atorvastatin endothelium dependent vasodilatory effects / Progesterone abolishes estrogen and/or atorvastatin endothelium dependent vasodilatory effects
Faludi, André Arpad; Aldrighi, José Mendes; Bertolami, Marcelo Chiara; Saleh, Mohamed H; Silva, Renata Alves; Nakamura, Yara; Pereira, Isabela RO; Abdalla, Dulcineia Saes Parra; Ramires, José Antonio Franchini; Jose Eduardo MR Sousa.
Afiliação
  • Faludi, André Arpad; Instituto Dante Pazzanese de Cardiologia. BR
  • Aldrighi, José Mendes; Instituto do Coração. BR
  • Bertolami, Marcelo Chiara; Instituto Dante Pazzanese de Cardiologia. BR
  • Saleh, Mohamed H; Instituto Dante Pazzanese de Cardiologia. BR
  • Silva, Renata Alves; Instituto Dante Pazzanese de Cardiologia. BR
  • Nakamura, Yara; Instituto Dante Pazzanese de Cardiologia. BR
  • Pereira, Isabela RO; Universidade de São paulo. BR
  • Abdalla, Dulcineia Saes Parra; Universidade de São Paulo. BR
  • Ramires, José Antonio Franchini; Instituto do Coração. BR
  • Jose Eduardo MR Sousa; Instituto Dante Pazzanese de Cardiologia. BR
Atherosclerosis ; Atherosclerosis;177(01): 89-96, nov 2004.
Article em En | SES-SP, SESSP-IDPCPROD, SES-SP | ID: biblio-1060106
Biblioteca responsável: BR79.1
Localização: BR79.1
RESUMO
This double blind randomized placebo controlled study assessed the effects of atorvastatin, estradiol and norethisterone, isolated and in combination, on the lipid profile and on vascular reactivity, in post-menopausal women with hypercholesterolemia and arterial hypertension. Ninety-four women aged 50–65 were selected. All have received dietary counseling (4 weeks), placebo (4 weeks), and drug therapy (12 weeks) 17- estradiol 2mg/day (E) (n = 17); E + norethisterone acetate 1 mg/day (P) (n = 18); torvastatin 10 mg/day (A) (n = 20); E + A (n = 21) and E + P + A (n = 18). All treatment modalities have significantly reduced total cholesterol (TC) (E = 8.8%, E + P = 10.1%, A = 27.9%, A + E = 29.4% and E + P + A = 35.7%) and LDL-cholesterol (LDL-c) levels (E + P + A = 46.6%, E + A = 45.9%, A = 40.2%, E = 20.3%, and E + P = 12.1%). As concerns HDL-cholesterol (HDL-c), Groups E and E + A had increases of 15.5% and 13.1%, respectively. The addition of a progesterone compound reduced its concentration (Group E + P = −9.1%, and Group E + P + A = −9.5%). By random, approximately half of the patients in each group were designated to the endothelial function evaluation (brachial artery ultrasound). We observed that in Group A (n = 10), in Group E (n = 10) and with the association (Group E + A) (n = 7), there was a significant increase in the flow-mediated vasodilatation as compared to basal measurements. The addition of a progestin has annulled these benefits.

Conclusions:

Atorvastatin has promoted more beneficial effects on TC and LDL-c, whereas estradiol was responsible for an increase in HDL-c. The addition of a progesterone derivative abolished these benefits. Atorvastatin, estradiol or both together improved endothelial function, an effect suppressed by the addition of norethisterone.
Assuntos
Buscar no Google
Adicionar na Minha BVS
Imprimir
XML
Coleções: 06-national / BR Base de dados: SES-SP / SESSP-IDPCPROD Assunto principal: Menopausa / Endotélio Vascular / Terapia de Reposição Hormonal / Hipercolesterolemia / Hipertensão Tipo de estudo: Clinical_trials Idioma: En Revista: Atherosclerosis Ano de publicação: 2004 Tipo de documento: Article
Buscar no Google
Adicionar na Minha BVS
Imprimir
XML
Coleções: 06-national / BR Base de dados: SES-SP / SESSP-IDPCPROD Assunto principal: Menopausa / Endotélio Vascular / Terapia de Reposição Hormonal / Hipercolesterolemia / Hipertensão Tipo de estudo: Clinical_trials Idioma: En Revista: Atherosclerosis Ano de publicação: 2004 Tipo de documento: Article